Cytogenetic and fluorescence in situ hybridization studies were successfully performed in 217 chronic lymphocytic leukemia (CLL). In all, 13 patients with 6q21 deletion were identified and characterized in comparison with 92 patients with 'favourable' karyotype (normal or 13qÀ), 69 cases with 'intermediate risk'
Introduction
Cytogenetic features have an important role in the definition of distinct disease subsets in B-cell chronic lymphocytic leukemia (CLL). [1] [2] [3] [4] [5] Early in the 1990s, conventional cytogenetic analysis (CCA) demonstrated that approximately 50% of CLL cases may show clonal aberrations and that specific cytogenetic patterns have independent prognostic significance. 6 A complex karyotype was associated with an inferior outcome and patients with trisomy 12 in their karyotype were shown to survive less than patients with 13qÀ or with normal karyotype. 7 Later on, fluorescence in situ hybridization (FISH) techniques demonstrated that up to 80% of the cases may carry a chromosomal defect in interphase cells, 8 giving the opportunity to better analyze the correlations of cytogenetic lesions and clinicobiological features. Convincing evidence was provided that: (a) 13q deletion occurring as an isolated chromosome lesion is associated with typical morphology and a benign clinical course; 4, 5 (b) patients with trisomy 12 usually display an excess of large lymphocytes identifying the CLL mixed-cell-type variant of the FAB classification; 9, 10 (c) 11q22-23 and 17p13 deletion may identify specific clinicopathological subsets of CLL having an inferior outcome. [11] [12] [13] A hierarchical cytogenetic classification was finally defined as having a strong correlation with the clinical outcome. 14 Given the importance of recognizing correlations between cytogenetic and clinicobiological features in CLL, the significance of novel recurring aberrations is currently under scrutiny. 15 The 6qÀ chromosome is know to occur at a relatively low frequency in CLL, having been reported in 3-6% of the cases by CCA and by FISH, 7, 16 mostly as a secondary chromosome anomaly or in the context of complex karyotypes. 17 The 6qÀ anomaly did not appear to influence survival in previous studies. 5, 15, 13 An association was found between 6qÀ and a high white blood cell (WBC) count, more extensive adenopathy at presentation 15 and shorter treatment-free interval (TFI). 18 The latter finding, however, was not confirmed in another study, 16 showing no difference in terms of clinical behavior between CLL with and without 6qÀ.
We have identified a group of patients with CLL carrying a 6q21 deletion among 273 cases studied at our Institution. The results of clinicobiologic and cytogenetic studies in these patients are presented in this report, with reference to the following questions: (a) is CLL with 6qÀ a cytogenetic entity? (b) does the 6qÀ occurring as an early chromosome change identify a disease having distinct hematological features? (c) how does CLL with 6qÀ compare in terms of clinical behavior with other cytogenetic subsets of CLL?
Materials and methods

Patients
Between 1985 and 2002, 273 patients with CLL seen at our Institution were enrolled in this study and submitted to cytogenetic analysis. Blood samples for cytogenetic analysis were obtained at or close to the time of presentation in 202 patients; 71 patients were analyzed during the course of the disease (median time from diagnosis 22 months). Cases with mantle cell lymphoma in leukemic phase, Waldenstrom's macroglobulinemia and prolymphocytic leukemia were excluded. Diagnosis was based on the presence of persistent lymphocytosis, the examination of the peripheral blood (PB) smears and the results of immunophenotyping. All patients showed the classical morphology (typical CLL), or they presented 15-55% large lymphocytes or prolymphocytes (atypical CLL, including CLL mixed-cell type and CLL/PL). 9 The following markers were tested in all cases by cytofluorimetric analysis as described previously, using a 30% cutoff for positivity in the lymphocyte gate:
19 CD5, CD19, CD23, CD22, CD25, CD11c, CD10 and CD103 antigens, the FMC7 monoclonal antibody and the expression of surface immunoglobulins. The presence of CD5 þ /CD19 þ lymphocytes with k/l chain restriction was a diagnostic requirement. Starting from 1999, the coexpression of the CD38 and CD19 antigens was tested on fresh PB cells, using commercially available reagents (Becton Dickinson, San Jose CA, USA), with a 20% cutoff for positivity.
All patients underwent physical examination, chest X-ray film and abdomen ultrasonography as part of the diagnostic workup. Routine laboratory investigations including blood count and serum biochemical profile were performed in all cases. As a rule, bone biopsy was performed in young patients (o60 years of age). Histologic studies were performed for diagnostic purposes in selected cases.
Indications for treatment included a rise in the WBC count with o12 month lymphocyte doubling time, the development of anemia, neutropenia or thrombocytopenia due to BM infiltration or autoimmune phenomena and disease progression in the Rai/Binet staging systems. 20, 21 The patients were treated according to guidelines in use at our Institution during the study period. Intermittent chlorambucil administration was used as first-line therapy in the majority of cases. In young patients, treatment included cyclophosphamide, vincristine, prednisone, with or without an anthracycline drug (C(H)OP regimens). Fludarabine was used since 1995 in refractory or relapsing patients and, since 1998, as front-line therapy in selected cases.
Design of the study
All 273 patients were studied by conventional chromosome analysis (CCA). Interphase FISH using a 6q21 probe was performed in all cases and the patients with 6qÀ as an early chromosome defect (group 1) were compared with the other CLL stratified into three cytogenetic groups (ie favourable (group 2), intermediate (group 3) and unfavourable (group 4), vide infra). For an accurate stratification of the patients according to the cytogenetic risk, all the patients with normal karyotype, with 1-2 clonal aberrations and with complex karyotype were assessed by FISH using 12q13, 11q/ATM and 17p/p53 probes, these aberrations having an established prognostic significance in CLL. The 13q14 probe was not used because the presence of 13q deletion would not have modified the allocation of the patient in the appropriate risk category.
Patients with 6q: Those patients with 6q21 deletion detected by CCA and/or by FISH were characterized by FISH analysis for the detection of occult deletions of 13q14, 11q22-23/ATM, 17p13/p53 and for the presence of trisomy 12. Based on cytogenetics and interphase FISH data, a group with 6qÀ as an early chromosome defect was identified fulfilling the following criteria: (i) the 6q21 deletion was present in all abnormal metaphase cells; (ii) absence of trisomy 12, 11q22-23 or 17p13 deletion by FISH analysis; and (iii) absence of a complex karyotype, defined by the presence of three or more aberrations in the same clone. The patients with 6qÀ were studied by morphologic, immunologic and genetic studies. Hematologic and clinical data were reviewed and collected in all cases included in this study.
Comparison with other cytogenetic groups: Clinicobiologic data in the 6qÀ group (group 1) were compared with similar data in the remaining cases, which were divided into three cytogenetically defined risk groups: the 'favourable' group (group 2) included those patients with normal karyotype or with 13qÀ as the sole anomaly in their karyotype; the 'intermediaterisk' group (group 3) included those patients with 1-2 clonal aberrations, including trisomy 12; the 'unfavourable' group (group 4) included those patients with complex karyotype (three or more clonal aberrations in their karyotype) or with 17pÀ or 11qÀ. These groups were defined taking into consideration previous studies documenting the prognostic significance of specific cytogenetic patterns in CLL. 6, 14 Cytogenetic analysis, interphase cytogenetic studies and IGVH analysis
Methods in use at our laboratory for CCA and FISH in lymphoproliferative disorders were described in detail. 22, 23 The following mitogens were used in all cases: phorbol myristate acetate at a final concentration of 50 ng/ml and lipopolysaccaride from Escherichia coli at a concentration of 0.1 mg/ml. Whenever possible, 20 karyotypes were analyzed and aberrations were described according to the ISCN. 24 The following probes for interphase FISH were employed as described previously 23 using the same sample that had been submitted to cytogenetic analysis: a 6q21 probe (a gift from Professor Brigitte Schlegelberger, Institute of Human Genetics, University of Kiel, Germany), prepared as described previously; 25 a chromosome 12-specific pericentromeric probe (Oncor, Gaithersburg MD, USA), the C21 cosmid detecting sequences at the 13q14 band, distal to the Rb gene, 26 a commercially available 17p13 probe recognizing p53 gene sequences (Vysis Co, distributed by Abbott, Rome, Italy), 11q22-23 probes recognizing ATM gene sequences 27 (QBiogene, distributed by Resnova, Genzano di Roma, Italy). The sensitivity limit for the detection of trisomy and deletion with these probes was 43 and 45% interphase cells with three and one signal, respectively. Dual color FISH using a differently labelled control probe and a test probe was performed and signal screening was carried out on at least 200 cells with welldelineated signals. Hybridization was repeated in those slides with less than 80% cells showing two control-probe signals.
V H genes were amplified from genomic DNA. DNA was extracted from cryopreserved CLL cells using Trizol reagent (Life Technologies, Paisley, Scotland). We performed a set of eight family-specific polymerase chain reactions to isolate the . In all the reactions, the same antisense J H degenerate primer was employed (J H deg: 5 0 -CTY ACC TGA RGA GAC RGT GAC C-3 0 ). The 30 ml reactions (10 pmol of each primer, 2.5 mM MgCl 2 , 100 mM of each dNTPs and 1 U Ampliterm Hot Start DNA polymerase in supplied buffer Fisher) were cycled 35 times at an annealing temperature of 601C. PCR products were spin column purified (Promega) and directly sequenced using the automated sequencer.
Sequence alignment was to the Entrez database (National Center for Biotechnology Information, NCBI, Bethesda, MD, USA) and to the V Base (MRC Center for Protein Engineering, Cambridge, UK. The cutoff of 98% homology to the germline sequence was chosen to discriminate between mutated (o98% homology) and unmutated (498% homology) cases, as reported previously. 28 
Statistical analysis
The Mann-Whitney test and the Kruskall-Wallis test were used for quantitative variables. Fischer's exact test was applied for categorical variables. All tests were two-sided. Patient survival was estimated by the Kaplan-Meier method from the date of diagnosis until death due to any cause or until the last patient follow-up. The survival curves were statistically compared by the log-rank test. In accord with previous studies, [11] [12] [13] a P-value of 0.05 was used as the criterion for statistical significance. Proportional-hazards regression analysis was used to identify the most significant independent prognostic variables on survival and P-values of less than 0.05 were considered statistically significant.
Results
Cytogenetic groups
A preliminary methodological problem in this study was represented by the definition of different cytogenetic groups. As cytogenetic findings and interphase FISH data have an established prognostic importance in CLL, 6, 14 we adopted a 'mixed' cytogenetic/FISH classification. Thus, each patient was allocated in a single cytogenetic category according to the following hierarchy: complex karyotype or 17pÀ or 11qÀ ('unfavourable' -group 4); 1-2 anomalies in the karyotype or þ 12 ('intermediate' -group 3); 6qÀ (group 1); normal or 13qÀ ('favourable' -group 2). Owing to the relatively small number of cases in each cytogenetic group, caution will be exercised in the interpretation of the clinical correlations.
Cytogenetic and FISH analysis using the 6q21 probe were performed in 273 cases. In all, 56 patients were excluded from further analysis because cytogenetic analysis had failed (o10 analyzable mitoses in 29 cases) or because insufficient hematologic data could be retrieved (27 cases).
A 6q21 deletion was detected by CCA and/or by interphase FISH analysis (21-92% of nuclei with 1 6q21-probe signal) in 20 patients, giving a 7.3% incidence (20/273 cases) for this chromosome lesion. Four cases were not considered as having 6qÀ as an early chromosome defect due to the presence of trisomy 12 and were included in the intermediate group; three cases were included in the unfavourable group due to the presence of a complex karyotype (two cases) and of 11qÀ (one case). Thus, 13 cases with 6qÀ as an early chromosome defect (group 1) were identified among 217 CLL patients with a complete set of cytogenetic and hematologic data. In three cases, a 13q14 deletion was detected by FISH, but this was not an exclusion criteria because the 13qÀ ranked last in the hierarchical cytogenetic classification of CLL. 14 A total of 92 cases, 10 of which had a 13qÀ chromosome in the karyotype, were included in group 2 ('favourable); 69 cases, 30 of which had trisomy 12, were included in group 3 ('intermediate'), and 43 cases, 35 of which had 11qÀ or 17pÀ were included in group 4 ('unfavourable').
Cytogenetic findings, IGVH status and cytologic features in 13 patients with 6qÀ
Cytogenetic analysis showed a 6qÀ chromosome in seven cases; six additional cases with normal karyotype were shown by FISH to carry a 6q21 deletion. Salient cytogenetic and genetic data in these 13 patients (group 1) are shown in Table 1 ; hematologic data are summarized in Table 2 . FISH documented the presence of 21-92% interphase cells with 6qÀ and the absence of other classical cytogenetic defects (absence of trisomy 12, 11qÀ or 17pÀ). Four out of 10 cases tested had less than 2% mutations in their IGVH genes (Table 1) . A majority of small lymphocytes with condensed chromatin and inconspicuous nucleoli were observed in all cases, with the picture of typical CLL in seven cases. In six cases, a diagnosis of CLL mixed-cell type was made according to the FAB criteria 9 due to /l, the Rai staging system was used. b ++, bright expression of sIg or CD22; scoring system according to Matutes et al 5, 9 (see text for discussion): one point for CD5+, CD23+, CD22+weak; FMC7À; sIg+weak. c Patients with 'unmutated' IGVH genes (see Table 1 ). SL: small lymphocytes; LL: large lymphocytes; LPL: lymphoplasmacytic cells or immunoblast-like cells; PL: prolymphocytes; BM: bone marrow; LN: lymph node; ND: not determined.
the presence of 415% large lymphocytes, lymphoplasmacytoid cells and immunoblast-like cells (see Table 2 and Figure 1 ). Prolymphocytoid cells were seen at a o10% frequency, whereas cleaved lymphocytes were only seen occasionally.
Immunophenotype was typical for CLL in 11 cases, with high scores (score 4-5) according to Matutes et al, 29 whereas CD23 negativity and FMC7 positivity were recorded in two cases (score 3). CD19/CD38 antigen coexpression was found in 43-65% cells in the lymphocyte gate in 5/6 cases tested.
Histologic data were reviewed in five patients. All cases had a histological picture consistent with CLL/small lymphocytic lymphoma according to the REAL classification. 30 In three cases with lymph node section available for review, a mixture of small and large cells, often constituting pseudoproliferation centers was noted, with an excess of prolymphocytes and scattered paraimmunoblasts (see Figure 1) . A diffuse pattern of bone marrow infiltration was observed in three cases, with significant infiltration by prolymphocytes in two (see Table 2 ).
Correlation of cytogenetic features and clinicobiologic parameters
Complete cytogenetic and clinical data could be collected in 217 patients (139 males and 78 females). The median age was 65 years (range 32-85 years); 163 patients had limited disease (Rai stages 0-1); 54 were diagnosed in Rai stages 2-4. The mean follow-up time for the entire series was 76 months; 80 patients died during the study period with a median overall survival of 121 months. CLL-unrelated deaths were not observed in the 6qÀ group. Hematologic and clinical data in cytogenetic groups 1-4 are detailed in Table 3 .
Comparison of 13 patients with 6qÀ and the remaining 204 patients without 6qÀ as an early chromosome defect showed that the WBC count (P ¼ 0.013); CD38 positivity (P ¼ 0.04); and atypical morphology (P ¼ 0.03) were associated with 6qÀ. No difference was found when considering age, hemoglobin, platelets, stage, LDH, ECOG performance status, splenomegaly, adenopathy, TFI and survival.
When comparing hematologic features in groups 1 and 2, the following features were found to be associated with the 6qÀ group: higher WBC count, splenomegaly, atypical morphology, CD38 positivity, short time from diagnosis to first treatment and shorter survival (see Figure 2 and Table 3 ). A higher median WBC count was found in group 1 with respect to group 3, and survival was shorter in group 4 than in group 1 (see Table 3 and Figure 2 ).
To ascertain if the 6qÀ anomaly was an independent factor predicting for an inferior outcome among those patients with 'favourable' cytogenetics, we performed an analysis of prognostic factors in 105 patients (92 favourable plus 13 with 6qÀ). As shown in Table 4 , the hematologic parameters having an impact on survival in these patients were advanced stage, atypical morphology, the 6qÀ chromosome, a high WBC count, age and CD38 positivity. The 6qÀ chromosome maintained its prognostic significance at multivariate analysis (P ¼ 0.02) along with stage (P ¼ 0.01).
The same type of analysis was performed pooling 13 cases with 6qÀ and 43 with an unfavourable karyotype (groups 1 and 4): the 6qÀ and a better performance status (low ECOG score) were independent factors predicting for a better outcome (P ¼ 0.01 and 0.001, respectively). The 6qÀ was not a prognostic factor when analyzing 82 patients with 6qÀ and intermediate karyotype (groups 1 and 3 ).
Discussion
The 6qÀ is a cytogenetic entity of CLL This study shows that a minority of CLL cases (4.7% in this series) may carry 6qÀ as an early chromosome defect defining the stem line. Seemingly, the transformation process in these patients involved DNA loss at 6q21, 25 and additional cytogenetic defects developed through a parallel route not involving chromosomes 12, 11q and 17p. Thus, the 6qÀ chromosome may identify a distinct cytogenetic entity of CLL, although in a minority of cases it may be associated with a 13q14 deletion. In previous analyses using cytogenetic and FISH techniques, an isolated 6q deletion was only reported occasionally, 14, 31, 32 and a detailed analysis of hematologic and clinical features was not performed in these studies. In a molecular genetic study, allelic loss at 6q was detected in up to 15% of informative CLL patients, showing that 6q deletion may be an important event in the molecular pathogenesis of some CLL cases. 33 Interestingly, recurrent chromosome aberrations were recently described in CLL that were not associated with the classical 13qÀ, 17pÀ, 11qÀ, þ 12 anomalies, 15 suggesting that a distinct minority of CLL cases may develop through novel cytogenetic routes. 
CLL with 6qÀ shows distinct hematological features
Our patients with 6qÀ showed some peculiar hematological features. Large lymphocytes and lymphoplasmacytic cells including immunoblast-like cells were seen frequently, whereas cleaved lymphocytes were only seen occasionally and prolymphocyte-like cells did not exceed 10% in the PB. Thus, a diagnosis of CLL mixed-cell type was felt to be appropriate in six out of 13 cases. Studies on lymph node sections and bone biopsies in five cases confirmed these findings, showing that an excess of paraimmunoblast-and prolymphocyte-like cells occurred frequently, together with a diffuse infiltration pattern in the bone marrow.
Interestingly, similar cytologic findings were described in patients with 6qÀ and small lymphocytic lymphoma, the lymphomatous counterpart of CLL. 34 Some cases with 6qÀ and atypical CLL were described previously by Hernandez et al. Despite the presence of atypical morphology, 11/13 cases in this study displayed the typical immunophenotypic profile described in classical CLL by Matutes et al, 29 with minor deviations occurring in two cases. Attention was recently devoted to the CD38 antigen as a possible new prognostic marker in CLL, [35] [36] [37] but there is disagreement in the literature on the ideal cutoff for CD38 positivity. Five out of six 6qÀ cases tested in our study showed unequivocal CD38 expression in 440% cells and this marker was more frequently found in the 6qÀ group with respect to all other CLL cases. Even though the transition of a CD38À to a CD38 þ status is a rare event, 37 recent analyses showed that CD38 expression may vary during the course of the disease, 38 and that its prognostic predictivity may be outweighed by cytogenetic and genetic markers. 28, 39 Therefore, we analyzed the mutational status of the IGVH gene and found a 60% incidence of somatic mutations in our 6qÀ patients. There are no data in the literature concerning the frequency of IGVH mutations in CLL with 6qÀ and our findings place this cytogenetic subset of CLL in an intermediate position between the patients with 11qÀ/17pÀ (unmutated set of IGVH gene in the majority of cases), and the patients with isolated 13qÀ (usually showing somatic mutations). Interestingly, an approximately 50% incidence of umutated IGVH genes was found in CLL with trisomy 12, 28,40 a chromosome aberration identifying a group of patients with an intermediate prognosis. 6 According to the IGVH mutational status, CLL with 6qÀ may be heterogeneous in terms of the cell of origin and it is worth noting that three patients with 6qÀ and 'unmutated' genes were alive at 41-84 months (nos. 1, 2, 9 in Table 2 ) and 1 patient (no. 7) died at 180 months, suggesting that this genetic feature was not 'per se' strictly associated with a dismal outcome in this cytogenetic subset of CLL.
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The 6qÀ is associated with intermediate prognosis
In previous studies analyzing survival in CLL according to specific chromosome lesions, patients with 6qÀ were allocated in a heterogeneous cytogenetic category (including 3q trisomy, 8q trisomy 14q32 anomalies), having a high probability of survival. 14 No difference in terms of the clinical outcome was previously noted between 6qÀ patients and other patients with CLL. 7, 16 In keeping with these findings, we were not able to demonstrate any difference in terms of survival in 13 patients with 6qÀ as compared with 204 patients without this anomaly. When comparing the 6qÀ group with other CLL cases, a significant difference was only found in the initial WBC count and in the frequency of atypical morphology, as suggested previously. 16, 18 In addition, we were able to document an association between CD38 positivity and 6qÀ in 117 assessable cases.
As CLL is a heterogeneous disease, we chose to identify three cytogenetically defined risk groups with which to compare the 6qÀ group. There is unequivocal evidence that complex karyotypes, 11qÀ and 17pÀ, predict for an inferior outcome in CLL and that isolated 13q deletion or a 'normal karyotype' has a favourable prognostic significance. An 'intermediate'-risk group was identified in this study because there is evidence that those patients with 1-2 chromosome anomalies, including trisomy 12 as detected by karyotype analysis, may fare worse than patients with normal karyotype. 6, 28 With respect to CLL with 'favourable' and 'intermediate' cytogenetic risk, our patients with 6qÀ showed a higher WBC count, whereas other clinically important presentation features such as age and stage were not found to differ significantly in these groups. Interestingly, we documented the need for early treatment and a clear survival disadvantage for 6qÀ patients vs patients allocated in the 'favourable' karyotype group. It is worth noting that chromosome 6 deletions involving the midportion of the long arm were associated with an inferior outcome in patients with low-grade lymphomas. 41, 42 In conclusion, we have shown that CLL with 6qÀ may represent a cytogenetic and clinicobiological entity, showing a distinct phenotypic and hematologic profile. These patients usually present a relatively high WBC count, classical immunophenotype, CD38 positivity and they feature a therapydemanding disease. The presence of atypical morphology and of IGVH mutations in a fraction of the cases suggests that the patients may be biologically heterogeneous, as is the case with other cytogenetic subsets of CLL (f.i. CLL with trisomy 12). These features are in keeping with the observed clinical outcome that clearly places CLL with 6qÀ in an intermediate-risk group. These findings may have practical implications for the definition of risk-adapted treatment, especially in young patients.
